Introduction
The Human CD272/BTLA HEK293T Stable Cell Line is a valuable tool for studying the structure, activity and potential therapeutic applications of the immune checkpoint protein B and T lymphocyte attenuator (BTLA). This stable cell line is derived from human embryonic kidney cells (HEK293T) and has been genetically modified to express the CD272/BTLA protein. In this article, we will provide a detailed description of the structure, activity and potential applications of this stable cell line.
Structure of CD272/BTLA Protein
The CD272/BTLA protein is a type I transmembrane protein that belongs to the immunoglobulin superfamily. It is composed of an extracellular domain, a transmembrane domain and a cytoplasmic tail. The extracellular domain contains an immunoglobulin variable-like (IgV) domain and an Ig constant-like (IgC) domain, which are involved in ligand binding. The transmembrane domain anchors the protein to the cell membrane, while the cytoplasmic tail contains signaling motifs that regulate the activity of the protein.
Activity of CD272/BTLA Protein
The CD272/BTLA protein is a co-inhibitory receptor that is primarily expressed on T and B lymphocytes. It interacts with its ligand, herpesvirus entry mediator (HVEM), which is expressed on antigen-presenting cells. This interaction leads to the recruitment of phosphatases and the inhibition of T cell receptor (TCR) signaling, resulting in the suppression of T cell activation and proliferation. The CD272/BTLA protein also plays a role in regulating the function of regulatory T cells and is involved in the maintenance of immune tolerance.
Applications of CD272/BTLA HEK293T Stable Cell Line
The CD272/BTLA HEK293T Stable Cell Line has a wide range of potential applications in the field of immunology and cancer research. Here are some examples:
1. Characterization of CD272/BTLA Protein
The stable expression of CD272/BTLA in HEK293T cells allows for the easy purification and characterization of this protein. This is useful for studying the structure, function and binding partners of CD272/BTLA, as well as for the development of therapeutic agents that target this protein.
2. Screening for CD272/BTLA Agonists and Antagonists
The CD272/BTLA HEK293T Stable Cell Line can be used in high-throughput screening assays to identify compounds that modulate the activity of CD272/BTLA. This can aid in the discovery of potential agonists or antagonists that can be further developed as immunomodulatory drugs.
3. Flow Cytometry Analysis of CD272/BTLA Expression
The stable expression of CD272/BTLA in HEK293T cells allows for the production of a large quantity of this protein, which can be used as a positive control in flow cytometry experiments. This can aid in the detection and quantification of CD272/BTLA expression on different cell types and under different conditions.
4. Investigating the Role of CD272/BTLA in Cancer
The CD272/BTLA protein has been implicated in the development and progression of various types of cancer. The CD272/BTLA HEK293T Stable Cell Line can be used to study the role of this protein in cancer biology, as well as to evaluate the potential of targeting CD272/BTLA as a therapeutic strategy for cancer treatment.
5. Development of Immunotherapies
The CD272/BTLA protein is a promising therapeutic target for the treatment of autoimmune diseases and cancer.
There are no reviews yet.